NVIDIA CORP
Institutional investor · Portfolio as of Q2 2025
SEC EDGAR SourceSEC Filings
NVIDIA CORP manages $4.3B across 6 positions as of Q2 2025. Top holdings: CRWV (91.4%), ARM (4.1%), APLD (1.8%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 3/5.0.
Q2 2025 Summary
Increased 1. Top move: CRWV (INCREASED, conviction 65). Portfolio: $4.3B across 6 positions.
Top holdings by portfolio weight
CRWV91.36%
ARM4.11%
APLD1.79%
NBIS1.52%
RXRX0.90%
WRD0.32%
Portfolio allocation by GICS sector
Technology97.58%
Communication Services1.52%
Healthcare0.90%
Behavioral investing profile
7-dimension quality assessment
Solid(3.0 / 5.0)
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Upgrade to Pro to see the worst-performing positions.
View plansCost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Holdings6 positions
Activity:
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
COREWEAVE INC | 24.3M | $4B | 91.4% | $40.47 | +295.33% | 2 qtrssince 2025-Q1 | Increased 65 |
ARM HOLDINGS PLC | 1.1M | $178.1M | 4.1% | $75.14 | +120.20% | 7 qtrssince 2023-Q4 | Unchanged 0 |
APPLIED DIGITAL CORP | 7.7M | $77.7M | 1.8% | $8.19 | +26.74% | 4 qtrssince 2024-Q3 | Unchanged 0 |
NEBIUS GROUP N.V. | 1.2M | $65.9M | 1.5% | $26.92 | +92.57% | 3 qtrssince 2024-Q4 | Unchanged 0 |
RECURSION PHARMACEUTICALS IN | 7.7M | $39M | 0.9% | $9.86 | -48.99% | 7 qtrssince 2023-Q4 | Unchanged 0 |
WERIDE INC | 1.7M | $13.7M | 0.3% | $13.85 | -42.02% | 3 qtrssince 2024-Q4 | Unchanged 0 |
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer